Introduction. Calcineurin inhibitors (CNIs) have an unfavorable cardiovascular risk profile in renal transplant recipients. The aim of this substudy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blood pressure monitoring and carotid intima media thickness. Methods. A total of 119 stable renal transplant recipients on a triple regimen with steroids, a CNI and MMF were randomized into either the concentration-controlled CNI or MMF withdrawal groups. Patients were treated for traditional cardiovascular risk factors according to predefined targets. Ambulatory blood pressure monitoring and measurements of intima media thickness were performed at baseline and after 1, 2 and 3 years after randomization. Results. CNI withdrawal resulted in a significant decline in both ambulatory day-and nighttime blood pressures (daytime: systolic blood pressure, -1.6 mm Hg/yr, P=0.018; diastolic blood pressure, -1.3 mm Hg/yr, P=0.002; nighttime: systolic blood pressure, -1.9 mm Hg/yr, P=0.008; diastolic blood pressure, -1.3 mm Hg/yr, P=0.014), which was not observed after MMF withdrawal. There was no difference in the proportion of nocturnal nondippers (both groups, 69%, P=0.95). Despite the reduction in ambulatory blood pressure, no effect of CNI withdrawal on carotid intima media thickness was found. Conclusion. In stable renal transplant recipients, late CNI withdrawal from a triple-drug regimen decreased blood pressure in comparison with MMF withdrawal, but had no specific impact on carotid intima media thickness. Considering the high prevalence of hypertension in patients on CNI therapy, most stable renal transplant recipients may benefit from late CNI withdrawal by improved blood pressure control.
CHAPTER 4
Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients 
INTRODUCTION
Cardiovascular disease remains the leading cause of mortality in renal transplant recipients. Attention is increasingly focused on traditional and nontraditional cardiovascular risk factors to improve the long-term outcome after renal transplantation 1 .
Arterial hypertension is highly prevalent in renal transplant recipients and has been associated with inferior graft outcome [2] [3] . Ambulatory blood pressure monitoring (ABPM) is considered superior to office blood pressure measurements in predicting endorgan damage and cardiovascular events [4] [5] . The absence of a nocturnal fall in blood pressure, known as nondipper pattern, is an additional prognostic factor and has been associated with left ventricular hypertrophy in patients with hypertension and in renal transplant recipients [6] [7] [8] [9] . The intima media thickness (IMT) of the common carotid artery is a marker of atherosclerosis and has been associated with an increased incidence of cardiovascular disease in the general population [10] [11] [12] and mortality in renal transplant recipients 13 . In clinical trials, IMT is often used as a surrogate endpoint to evaluate the treatment efficacy of antihypertensive or lipid-lowering drugs. Calcineurin inhibitors (CNIs) carry an unfavorable cardiovascular risk profile, including nephrotoxicity, hypertension, hypercholesterolemia and new-onset diabetes mellitus 14 .
Mycophenolate mofetil (MMF), however, has none of these cardiovascular adverse effects and may even be advantageous by reducing atherosclerosis, and preventing intimal hyperplasia and smooth muscle cell proliferation [15] [16] . Therefore, the withdrawal of CNIs from the immunosuppressive regimen could be a rational treatment approach to lower the cardiovascular risk. Early CNI withdrawal, however, has not become popular because of the increased risk of acute rejection 17 . In a randomized concentration-controlled study, the impact of late withdrawal of a CNI or MMF from a triple-drug regimen on renal function was recently evaluated 18 . CNI elimination resulted in better renal function, whereas the risk of acute rejection was low in both groups. Here, a cardiovascular substudy is reported, which investigated the impact of CNI withdrawal on ambulatory blood pressure and carotid IMT.
RESULTS

Study population
A total of 119 patients were enrolled in this cardiovascular substudy between December 2005 and September 2007. The baseline characteristics of the study population are summarized in Table 1 . The results show comparable demographic characteristics, and recipient, kidney donor and transplantation procedure-related factors. There were also no differences in the baseline clinical or cardiovascular risk parameters. 
Clinical follow-up
The clinical parameters of the patients at 3 years are shown in Table 2 . The results on renal function and treatment of hyperlipidemia and diabetes mellitus have been reported previously 18 . In short, after 3 years of follow-up, the CNI withdrawal group had a better estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula 19 as compared with the MMF withdrawal group (60.1±20.1 vs. 54.0±17.2 mL/min/1.73 m 2 , P=0.10; Table 2 ). In both groups, a significant decrease in low-density lipoprotein (LDL) cholesterol was observed (MMF withdrawal, P<0.001; CNI withdrawal, P=0.001), but no significant difference between the groups ( Table 2 ). The groups also did not differ in glycated hemoglobin (HbA1c) values or in the proportions of patients with diabetes mellitus (Table 2 ). In the first 6 months after withdrawal, three patients in the CNI withdrawal group experienced acute rejection versus one patient in the MMF withdrawal group (P=0.36). At 3 years, one patient in each group had returned to dialysis because of chronic allograft nephropathy (MMF withdrawal group) and chronic rejection (CNI withdrawal group). During the follow-up period, coronary events occurred in one patient in the CNI withdrawal group and three patients in the MMF withdrawal group (P=0.62). None of the patients experienced a cerebrovascular event. Three patients in the CNI withdrawal group and one patient in the MMF withdrawal group were treated for peripheral arterial disease (P=0.36). Two patients in the CNI withdrawal group and four patients in the MMF withdrawal group died during the 3-year follow-up (P=0.68). Three patients dropped out of the study because of posttransplant lymphoproliferative disease (CNI withdrawal group), peripheral vascular disease (CNI withdrawal group) and a Merkel cell tumour (MMF withdrawal group). Two and four patients in the CNI withdrawal and MMF withdrawal groups, respectively, withdrew their informed consent because of the perceived intensity of the outpatient visits.
Ambulatory blood pressure and intima media thickness
The results of the ABPM at baseline and 3 years after withdrawal are summarized in Table  3 . At baseline, there were no significant differences in the mean 24-hr, and the daytime Table  3 ) were significantly lower in the CNI withdrawal group. This was observed for blood pressures recorded during both the daytime and nighttime, but the proportion of nondippers remained similar in both groups (69%, P=0.95). The day-and nighttime blood pressures of the MMF withdrawal and CNI withdrawal groups are plotted in Figure 1 . The CNI withdrawal group demonstrated a significant decline in ambulatory blood pressure during the follow-up of the study (slope daytime SBP, -1.6 mm Hg/yr, P=0.018; slope Table 3 ). If linear trends were assumed, the slopes of ambulatory blood pressure were significantly different between the groups (daytime SBP, P=0.035; daytime DBP, P=0.001; nighttime SBP, P=0.015; nighttime DBP, P=0.003).
An analysis of the subgroups of patients, who were originally on cyclosporine (CsA) or tacrolimus, was also performed (see Table S1 , SDC, http://links.lww.com/TP/A818). The CsA subgroup showed similar results 3 years after withdrawal as compared with the whole study population. Patients had a significantly lower mean 24-hr SBP (123.1±7.9 Table S1 , SDC, http://links.lww.com/TP/A818). Moreover, in the tacrolimus subgroup, mean 24-hr ambulatory blood pressures were lower after tacrolimus withdrawal compared with MMF withdrawal (24- At 3-year follow-up, a significantly lower proportion of patients used more than two antihypertensive drugs in the CNI withdrawal group than in the MMF withdrawal group (35% vs. 57%, P=0.03; Table 2 ). Compared with baseline, more patients used more than two antihypertensive drugs at 3 years after MMF withdrawal (from 48% to 57%, P=0.04), whereas the proportion of patients who were CNI withdrawn with more than two antihypertensive agents did not increase (from 36% to 35%, P=1.00). There was no difference in the type of antihypertensive medication used between the groups, except for more use of β-blockers (59% vs. 39%, P=0.05) in the MMF withdrawal group (Table 2) .
At baseline, the mean IMT was not significantly different between the groups (MMF withdrawal, 0.605±0.092 mm; CNI withdrawal, 0.632±0.105 mm, P=0.13; Table 3 ). During the follow-up period, mean IMT did not significantly change over time in both groups (slope MMF withdrawal, -0.00145 mm/yr, P=0.50; slope CNI withdrawal, -0.00416 mm/ yr, P=0.14; slope difference, P=0.54; Figure 2 ) and after 3 years there was no significant difference in mean IMT between the withdrawal groups (MMF withdrawal, 0.591±0.070 mm; CNI withdrawal, 0.611±0.074 mm, P=0.27; Table 3 ). 
DISCUSSION
The results of this study demonstrate that, in stable renal transplant recipients, late CNI withdrawal significantly improved ambulatory blood pressures during both the daytime and nighttime recordings. No effect on intima media thickness was observed at 3 years after either late CNI or MMF withdrawal. Early CNI withdrawal is not popular because of the increased risk of acute rejection 17 .
The risk of acute rejection in studies with early CNI withdrawal has been associated with mycophenolic acid (MPA) exposure [20] [21] [22] . This study was conducted as a cardiovascular substudy of a randomized trial, which showed that late CNI withdrawal while providing adequate mycophenolate exposure resulted in better renal function with only a low risk of acute rejection 18 .
Arterial hypertension is highly prevalent in renal transplant recipients and has been associated with inferior graft outcome and increased cardiovascular mortality [2] [3] . CNIs may raise arterial blood pressure in transplant recipients by several mechanisms [23] [24] [25] , including arteriolar vasoconstriction, activation of the renin-angiotensin system, direct effects on juxtaglomerular cells and increased tubular sodium reabsorption [26] [27] [28] . In addition, CNIs disturb the balance between vasoconstriction and vasodilator factors and may directly activate the sympathetic nervous system 25, 29 . This study indicated that CNI withdrawal facilitated better blood pressure control compared with MMF withdrawal. Significantly less patients who had the CNI withdrawn required more than two antihypertensive drugs, which still resulted in better ambulatory blood pressure. The observed absolute decline in blood pressure was, however, small. The most likely explanation is that, despite a dedicated outpatient clinic setting and stringent treatment algorithm to achieve predefined blood pressure targets-SBP less than 130 mm Hg and DBP less than 85 mm Hg (in case of proteinuria, SBP less than 125 mm Hg and DBP less than 75 mm Hg)-it turned out more difficult to achieve these targets than anticipated. Approximately one third of patients (MMF withdrawal, 33%; CNI withdrawal, 31%) were treated with tacrolimus before randomization. A subgroup analysis of these patients showed a clear decline in 24-hr ambulatory blood pressures after tacrolimus withdrawal as compared with MMF withdrawal, close to reaching statistical significance. Although the subgroup analysis was not predefined in the protocol and the numbers of patients were small, these results suggest that, although CsA and tacrolimus inhibit calcineurin activity by means of interaction with different immunophyllines, they share a dose-dependent adverse effect on arterial blood pressure. Previously, the nephrotoxic potential of these two CNIs was found to be indistinguishable clinically [30] [31] , histologically 32 or at the renal molecular level 33 .
This study is the first to evaluate the impact of late CNI withdrawal on ABPM in stable renal transplant recipients. Compared with office blood pressure measurements, ABPM is generally considered a more precise method to evaluate the control of hypertension 34 . In addition, in renal transplant recipients, ambulatory blood pressure is also a better predictor of end-organ damage, such as left ventricular hypertrophy and renal allograft dysfunction 8, [35] [36] . A nondipper status, which is frequently found beyond the first year after renal transplantation (60-76%) [37] [38] [39] , has been associated with inferior graft function and may, at least partially, also be related to the use of CNIs twice daily 38, 40 .
Only a few studies have evaluated the effect of CNI-based immunosuppressive regimens on ABPM 8, [40] [41] [42] . Van den Dorpel et al. reported a decrease in mean 24-hr blood pressure and an increase in the nocturnal decline of mean blood pressure after the late conversion from CsA to azathioprine in 18 stable renal transplant recipients 40 . In contrast with this study, we did not observe any difference in the nocturnal fall in SBP (results not shown) or a higher proportion of nondippers in the MMF withdrawal group. Our findings compare well with a more recent study comparing ABPM in 38 patients on sirolimus or CNI-based maintenance immunosuppression 41 . In that study, patients on CNI maintenance therapy had a higher 24-hr SBP and a higher nighttime SBP and DBP. Two small cross-sectional studies observed more left ventricular hypertrophy in CsA vs. azathioprine-treated patients, which was associated with a higher ambulatory SBP 8, 42 .
To our knowledge, no prospective studies have been performed to examine the influence of either CNI or MMF withdrawal on IMT in renal transplantation. The IMT reflects the overall degree of (subclinical) atherosclerosis. In patients on hemodialysis and in renal transplant recipients, IMT has been associated with increased mortality 13, [43] [44] . Although IMT in renal transplant recipients is generally lower when compared with dialysis patients 45 , the values are still increased compared with healthy control subjects 43, [45] [46] [47] .
An increased IMT in renal transplant recipients has been associated with inferior graft outcome 48 . The data on the progression of IMT in renal transplant recipients in the longterm are, however, scarce and remain inconclusive, since previous studies in limited numbers of patients have reported either a reduction 49 , no change 50 or a progression 51 with time.
In this study, the mean common carotid IMT of the whole study population at baseline was 0.618±0.099 mm, which is comparable to values reported in previous studies in renal transplant recipients 43, [51] [52] [53] . CNIs have widely documented adverse effects on blood pressure, cholesterol, glucose metabolism and renal function, but no specific effect of CNI withdrawal on IMT was found during the 3-year follow-up period in this study. Hypertension and ambulatory blood pressure have been found to be determinants of IMT in the general population and hypertensive patients [54] [55] [56] . In this study, however, a significant reduction in ambulatory blood pressure after CNI withdrawal was not associated with a change of IMT. One could hypothesize that a longer follow-up period is necessary to detect the beneficial effect of blood pressure on IMT progression or that the differences in blood pressures observed in this study were too small. In this context, it is relevant to note that randomized trials evaluating the effect of antihypertensive medication have shown a reduction of IMT progression with smaller blood pressure differences 57 . In addition, the reduction in mean LDL cholesterol levels by statin treatment (from 3.1 to 2.6 mmol/L, 16% reduction) in the current study was associated with a stable IMT. Intensive lipid lowering has been associated with a reduction in the progression of IMT 58 and lipid lowering may have contributed to the stable IMT observed in this study.
Only one small prospective randomized study has examined the effect of pravastatin on IMT in renal transplant recipients and reported less progression after 1 year after a 26% reduction in mean LDL cholesterol (from 3.8 to 2.8 mmol/L) 51 .
A longer follow-up time and a larger sample size may be required to detect any significant alterations of IMT before robust conclusions can be made regarding the impact of either CNI or MMF withdrawal. Another potential shortcoming of the study is that it is a single-center study in mainly Caucasian transplant recipients, and the results may not be extrapolated to patients with another risk profile or those of different ethnic origin. Finally, this study did not include a control group, but it is not to be expected that blood pressure control would have improved in a control group continuing on CNI-based maintenance therapy. In conclusion, this study demonstrated that late CNI withdrawal from a triple-drug regimen facilitated better blood pressure control. No specific beneficial effect of either CNI or MMF withdrawal on carotid IMT was found. Considering the high cardiovascular risk in renal transplant recipients, most patients might benefit from better control of blood pressure by late CNI withdrawal.
MATERIALS AND METHODS
Patients and study design
The design of the main study and the detailed treatment plan have been published previously 18 . Briefly, the main study was a prospective, open-label, single-center, randomized controlled trial that enrolled 177 stable renal transplant recipients. In the first phase of the study, the safety of high-exposure dosing of MMF to an MPA target of 75 μg·hr/ mL (range, 60-90 μg·hr/mL) was tested and 58 patients were randomized (1:1:1) into the CNI withdrawal, MMF withdrawal or continuation of triple therapy with steroids groups. All patients were randomized with stratification for previous acute rejection and prior cardiovascular events (myocardial infarction, coronary bypass surgery or percutaneous coronary interventions). Patients were dosed using a population-based pharmacokinetic model with a Bayesian estimator and limited sampling [59] [60] . The targets for the area under the concentration-over-time curves (AUC 0-12 ) of CsA and tacrolimus were 3250 ng·hr/mL (range, 3000-3500 ng·hr/mL) and 120 ng·hr/mL (range, 100-140 ng·hr/mL), respectively. The MMF or CNI doses were reduced by 50% every 2 weeks and withdrawn after 4 weeks.
Patients on tacrolimus used prednisolone at 5 mg/day, and all other patients at 7.5 to 10 mg/day. Concomitant with withdrawal, the prednisone dose was temporarily increased to 20 mg (1 week), 15 mg (1 week) and then back to baseline. Based on the favorable results in these 58 patients, another 119 patients were included in the second phase of the main study. These patients participated in the current cardiovascular substudy (NCT00169910). The substudy was designed to investigate the effect of CNI or MMF withdrawal on ambulatory blood pressure and IMT. All patients were followed in a dedicated outpatient clinic and treated according to predefined target standards of care: SBP less than 130 mm Hg and DBP less than 85 mm Hg; in cases of proteinuria, SBP less than 125 mm Hg and DBP less than 75 mm Hg 61 . The target LDL cholesterol was less than 2.6 mmol/L for the entire population. The treatment of hypertension was guided by office blood pressures only. Study visits were scheduled every 3 months after trial entry during the first year, and subsequently, after 2 and 3 years. At baseline and on a yearly basis during the study, weight, blood pressure, laboratory parameters and concomitant medication were recorded. Office blood pressure was measured in a sitting position after 5 minutes of rest using a digital blood pressure monitor (OMRON; Kyoto, Japan). The mean was calculated from three measurements. Laboratory measurements included hemoglobin, serum creatinine, cholesterol, LDL cholesterol, HbA1c and urinary albumin-to-creatinine ratio. The trial was performed in conformity with the Declaration of Helsinki, Good Clinical Practice guidelines. Informed consent was obtained from all patients. The main study and the substudy were approved by the Leiden University Medical Center Ethics Committee.
Ambulatory blood pressure monitoring and intima media thickness
The main outcome parameters for the substudy were the change in ambulatory blood pressure and carotid IMT during a 3-year follow-up period. At baseline, and at 1,2 and 3 years after randomization, 24-hr ABPM were obtained and the IMT of the carotid arteries was assessed. 24-hr ABPMs were performed with a high-precision blood pressure monitor (Mobil-O-Graph; Vitalsys, Antwerp, Belgium). Measurements were performed every 20 minutes during daytime and every 30 minutes during nighttime. Dipping status was defined as a reduction in mean SBP of 10% or greater during the night compared with during the day. The common carotid artery was examined using high-resolution Bmode ultrasound with online radio frequency processing-based measurements (ArtLab; Esaota, Maastricht, The Netherlands). IMT was measured at the far wall of the common carotid artery 1 cm proximal to the bifurcation over a range of 15 mm in recumbent position and was defined as the distance between the leading edges of the lumen interface and the media-adventitia interface of the far wall. A total of six measurements of the left and right common carotid artery were performed at three predefined angles (left: 180º, 225º and 270º; right: 180º, 135º, 90º). The mean IMT was calculated from the measure-ments of both arteries. The assessment of IMT for individual patients during the study was performed by the same sonographer according to standardized procedures 62 . The results of the ABPM and carotid IMT were not known to the physicians that treated the patients in the study and, therefore, did not influence treatment decisions.
Statistical analysis
The analysis was performed on the basis of the intention-to-treat principle. Continuous variables are presented as mean±SD and categorical variables are presented as frequencies and percentages. Differences of continuous numeric variables between the CNI withdrawal and MMF withdrawal groups were evaluated using the unpaired Student t test or Mann-Whitney test. Nominal categorical variables were compared by a chi-square test or Fisher exact test. Linear mixed models were used to analyze the longitudinal data of ambulatory blood pressure, IMT and renal function in both withdrawal groups. The models of ABPM and IMT assumed that blood pressure and IMT had a linear trend during the follow-up period with a random slope and intercept. By plotting the crude data, a linear approach on ABPM and IMT over time was demonstrated to be acceptable. Several other models (including nonlinear models) did not improve the fit of the linear model to the data significantly. Mixed modeling was chosen because it allows analysis of all data, including those of subjects with missing values (assuming the missing measurements occurred at random). Other advantages of using mixed procedure included allowing analysis of uneven-spaced repeated measurements and handling random effects effectively. First, the null hypothesis was tested that the slopes of the trends over time did not differ between the two withdrawal groups. Second, the null hypothesis was tested that the change from baseline was zero within each group. A P-value less than 0.05 was considered to be statistically significant. All analyses were performed using the statistical software package SSPS (SPSS Inc.; Chicago, Illinois, USA; version 16.0) and R.10.2 63 . 
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